- Individuals & Families
- Businesses
- Partners & Agents
Your home is more than bricks and mortar. It’s full of memories and you're reflected in every detail. So if you experience a claim, you’ll most likely want your life back, and to rebuild without hassles, headaches, or delay.
Designed to cover you and your family in the event of accident-related injuries and disabilities.
We know that innovative products go hand in hand with superior service. At Chubb, we offer a range of value-added services and customised solutions for that added advantage to meet various needs.
Chubb leverages superior underwriting expertise and world renowned claims, account services, and financial strength to offer solutions for small and medium businesses.
Today's multinational organizations face complex and interconnected risks. We offer insurance solutions that are tailored to global needs as well as local requirements, helping them address their risk management challenges.
Chubb has a proven track record of maximising ancillary revenue for more than 120 business partners across the globe.
When the pandemic struck in 2020, Chubb and legal partner Kennedys produced a series of reports exploring the impact it was having on the life science industry through the lenses of clinical trials, medical devices, telehealth, genomics and the supply chain.
Looking back at the past two years, the industry has, by and large, proved successful at managing the most significant risks faced. It has also demonstrated its capabilities during an extraordinary time; producing vaccines at record speed and rapidly delivering solutions – from telehealth to medical devices and genomic surveillance – that have helped us through this difficult period. Now the life science sector is building on that foundation to improve healthcare and preparedness for future pandemics, while continuing to battle COVID-19.
Read “The New Normal in Life Science” report for insights on how those changes played out in the medium term. Which innovations have become part of the new normal and where did things go wrong? From the new strength and capacity that has been built in telehealth and clinical trials, to the lessons that have been learnt for future pandemics on medical devices and supply chains.
Key takeaways
- Supply chain visibility is now a key focus at c-level, enabled by technology.
- Decentralised trials could be here to stay but decentralising patient recruitment is still a way off.
- Genomic research still has a lot more to offer during this pandemic.
- Research needs to be more inclusive to ensure the benefits of genomics are enjoyed by all.
- Fostering innovation in the context of remote working is the next challenge.
Read more reports in the ‘Life Science in the era of pandemics’ series:
Emerging risks in COVID-19 clinical trials
Making medical devices during a pandemic
Insights and expertise
No part of this article may be reproduced in any written, electronic, recording, or printed form without written permission of Chubb.
Disclaimer - The content of the above article is not intended to constitute professional advice. Although all content is believed to be accurate, Chubb Insurance Singapore Limited (Chubb) makes no warranty or guarantee about the accuracy, completeness, or adequacy of the content of this article. Users relying on any content do so at their own risk.